Daily Chart

Merck & Co. Inc. (MRK) Financial News - Merck Receives Subpoena Related to Selling Three Medicines

Merck & Co. Inc. (MRK)

Merck Receives Subpoena Related to Selling Three Medicines

Quote: department asked for details of the marketing and selling of Temodar, PegIntron and Intron A, from January 1, 2004 to the present “in a federal health-care investigation,” Merck said today in a filing. “This is the first disclosure of this matter,” Ronald Rogers, a spokesman for Whitehouse Station, New Jersey-based Merck, said in an e-mail. The drugmaker is cooperating with the investigation, Rogers said, declining to provide additional information. brain cancer, accounted for $1.07 billion in sales last year. Intron A for cancer and PegIntron for hepatitis C together generated $946 million in sales. New York Stock Exchange composite trading, the lowest price since August 2009. The shares have declined 17 percent this year. Pfizer Inc. is the biggest U.S. drugmaker. orenick@bloomberg.net. rgale5@bloomberg.net ...
Open whole article (external link)

Other Financial and Stock Market News concerning Merck & Co. Inc.

Merck & Co. Inc. Stock Summary

Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.